![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC26A4 |
Gene summary for SLC26A4 |
![]() |
Gene information | Species | Human | Gene symbol | SLC26A4 | Gene ID | 5172 |
Gene name | solute carrier family 26 member 4 | |
Gene Alias | DFNB4 | |
Cytomap | 7q22.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O43511 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5172 | SLC26A4 | ATC12 | Human | Thyroid | ATC | 6.47e-43 | -1.07e+00 | 0.34 |
5172 | SLC26A4 | ATC13 | Human | Thyroid | ATC | 7.42e-37 | -1.09e+00 | 0.34 |
5172 | SLC26A4 | ATC1 | Human | Thyroid | ATC | 4.99e-10 | -1.10e+00 | 0.2878 |
5172 | SLC26A4 | ATC2 | Human | Thyroid | ATC | 3.09e-02 | -1.10e+00 | 0.34 |
5172 | SLC26A4 | ATC3 | Human | Thyroid | ATC | 2.06e-04 | -1.06e+00 | 0.338 |
5172 | SLC26A4 | ATC4 | Human | Thyroid | ATC | 2.62e-34 | -1.06e+00 | 0.34 |
5172 | SLC26A4 | ATC5 | Human | Thyroid | ATC | 5.73e-43 | -1.08e+00 | 0.34 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC26A4 | SNV | Missense_Mutation | c.311N>T | p.Ala104Val | p.A104V | O43511 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SLC26A4 | SNV | Missense_Mutation | c.1126N>A | p.Asp376Asn | p.D376N | O43511 | protein_coding | tolerated(0.13) | benign(0.246) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SLC26A4 | SNV | Missense_Mutation | novel | c.1486C>A | p.Leu496Ile | p.L496I | O43511 | protein_coding | tolerated(0.21) | benign(0.2) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC26A4 | SNV | Missense_Mutation | rs150597240 | c.2291N>T | p.Thr764Met | p.T764M | O43511 | protein_coding | tolerated_low_confidence(0.27) | benign(0.074) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC26A4 | SNV | Missense_Mutation | novel | c.2263N>G | p.Thr755Ala | p.T755A | O43511 | protein_coding | deleterious(0.02) | benign(0) | TCGA-BH-A1EY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229A>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229N>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229A>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SLC26A4 | SNV | Missense_Mutation | c.1819N>T | p.Asp607Tyr | p.D607Y | O43511 | protein_coding | deleterious(0.04) | benign(0.285) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229N>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |